Navigation Links
Intercell to Begin Phase II JE Vaccine Trials in India

Austrian biotech major, Intercell and its partner Hyderabad-based Biological E. Ltd. announced that they have obtained regulatory clearance to start// a pediatric phase II clinical trial for Intercell’s novel Japanese Encephalitis vaccine in India.

The randomized and controlled study aims to demonstrate the dose, safety and immunogenicity of Intercell’s JE vaccine compared to a locally produced mouse-brain Japanese Encephalitis vaccine.

The study, which will start in late April/early May, will enroll children at the age of one to three years. It is the first step towards the licensure of a new cell culture derived product in Asia, which is expected for late 2008/early 2009.

Mr Gerd Zettlmeissl, Chief Executive Officer of Intercell, said, “We have clearly defined a straight forward development process for our Japanese Encephalitis vaccine to enter endemic markets. It is our priority to make the vaccine, which is based on proven and safe technology, also available for the population and especially the children in endemic regions.”

Mr Vijay Kumar Datla, Chairman and Managing Director of Biological E. Ltd said, "We believe that this is a very important milestone in our endeavor to bring a safe and efficacious vaccine to endemic regions."

Source: BioSpectrum
SR/M
'"/>




Page: 1

Related medicine news :

1. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
2. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
3. Cancer Begins With Epigenetic Changes: Study
4. Learning About Healthy Diet Choices Begins At Schools
5. China Begins Human Trials For HIV/AIDS Drug
6. Pilot Study to Test Effect of Mobile Phone Transmissions On Skin To Begin In Finland
7. Preparation for Culling Begin at Belghat, Rajangaon and Dhaamnia
8. Make-Up Tips For Beginners
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Human Bird Flu Vaccine Trials Begin In Russia
11. Administration of Fish Drug for Asthma Patients Begins in Andhra
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... ... 19, 2017 , ... Yesterday, the President of the United States retracted his ... There are not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist ... NPEIV stands against all forms of such hatred and discrimination in this country and ...
(Date:8/19/2017)... Orlando, Fla. (PRWEB) , ... August 19, 2017 ... ... that Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain ... in anesthesiology, a focus on the treatment of migraine headaches, and significant experience ...
(Date:8/18/2017)... ... 2017 , ... Mr. Noppadon Pakprot, Deputy Governor for Tourism ... and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest “Functional & Regenerative ... and Business at TAT said, “Thailand has long been recognized as a world ...
(Date:8/18/2017)... ... ... ... For Immediate Release                Contact: Julian Teixeira, August ... Seek Sex and Relationship Advice from their Fathers , ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the importance ... for individuals with hearing impairments and shares the latest innovations in hearing aid ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
(Date:8/7/2017)... FLINT, Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: ... for the quarter ended June 30, 2017.  All comparisons, unless ... Second Quarter 2017 ... compared to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)... 2017  Agragen, LLC, a Cincinnati ... biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces a ... drug candidates, AGR131.  This drug is designed to ... blood of patients suffering from inflammatory conditions such ... Biological pharmaceuticals ...
Breaking Medicine Technology: